The therapeutic focus of Proluton (hydroxyprogesterone caproate) is generally directed toward providing proactive support and stability within specific high-risk gestational contexts, where its application addresses high-risk obstetric scenarios.

This medication is relevant for managing symptoms related to heightened physiological activity (premature contractility) across therapeutic domains including prophylaxis for recurrent spontaneous preterm delivery in singleton pregnancies, and provides hormonal support in specific fertility treatment protocols. It is applied across domains where additional symptomatic support is needed.

This application may assist with maintaining functional stability to support the continuation of the gestational period and contributes to easing the overall symptom load. For patients facing a history of recurrent adverse outcomes, this support may be considered relevant.

“It is commonly used to help with managing uterine irritability, which supports the patient during difficult episodes by easing distress.”

Quick Fact: Focus on Uterine Stability

This medication is typically used in clinical settings that involve unstable symptom patterns, offering symptomatic relief that helps patients cope more steadily with difficult episodes and assists with maintaining general functional stability.

Regulatory References

1. DailyMed Label for Hydroxyprogesterone Caproate

Who Can and Cannot Use Proluton? — Official Regulatory Information

The eligibility status for Proluton (hydroxyprogesterone caproate) is now severely restricted or prohibited based on the official actions of major governmental regulatory bodies.

Regulatory Status	Population	Official Basis
Approval Withdrawn	Pregnant women with a history of spontaneous singleton preterm birth (US indication)	US Food and Drug Administration (FDA) withdrew approval in April 2023 due to lack of demonstrated effectiveness and unfavorable benefit-risk assessment.
Marketing Suspended	All authorized uses (including prevention of preterm birth and certain gynecological disorders)	European Medicines Agency (EMA) concluded the benefits do not outweigh the risks, leading to suspension of marketing authorizations in the EU in 2024.

Formal Contraindications (Exclusions)

Individuals must not use this medicine if they have, or have a history of, certain severe medical conditions, including:

• Thromboembolic disorders (current or history of blood clots).
• Hormone-sensitive cancers (known or suspected breast cancer or other hormone-sensitive cancers).
• Liver disease (active liver disease or liver tumors, benign or malignant).
• Undiagnosed abnormal vaginal bleeding unrelated to pregnancy, or cholestatic jaundice of pregnancy.
• Uncontrolled hypertension.

Other Restrictions

Use was explicitly not intended or not studied in women with multiple gestations (twins, triplets, etc.) or pediatric patients.

Interactions with other medicinal products for Proluton (hydroxyprogesterone caproate) are structured around pharmacokinetic and pharmacodynamic considerations documented in official regulatory labeling.

Drug-Drug Interactions via Metabolism

The primary interaction pathway involves the extensive metabolism of Proluton, which is mediated by the cytochrome P450 isoenzymes CYP3A4 and CYP3A5. Co-administration with strong inhibitors of these enzymes, such as certain antifungal or HIV protease inhibitor agents, may reduce the drug's clearance, resulting in an expected increase in its plasma concentration. Conversely, strong enzyme inducers, including Rifampin, Phenytoin, or the herbal product St. John's Wort, are expected to increase metabolism, potentially leading to reduced plasma exposure. Regulatory documents indicate a minimal potential for clinically significant interactions with other CYP enzymes, such as CYP2D6 and CYP1A2.

Pharmacodynamic Interactions and Restrictions

Proluton carries two primary pharmacodynamic interaction considerations. First, progestins may impair glucose tolerance; thus, co-administration with antidiabetic agents requires close attention to glucose control. Second, an additive risk of thromboembolic events exists when the drug is combined with other agents that affect blood coagulation. Furthermore, use is strictly contraindicated in patients with active liver disease. This is a clearance-dependent restriction, as extensive metabolism is required for drug elimination, and hepatic impairment may reduce the elimination rate.

Proluton is a synthetic progestin, hydroxyprogesterone caproate, which functions as an agonist at the intracellular progesterone receptor (PR). The compound binds to both PR-A and PR-B isoforms, which are ligand-activated transcription factors present in target tissues, including the uterus and cervix.

Upon binding, the activated receptor complex translocates to the nucleus and modulates gene transcription by interacting with specific DNA sequences (Progesterone Response Elements). This molecular pathway leads to altered expression of target genes involved in tissue development and maintenance. Within the myometrium, this results in decreased excitability and reduced contractility of the uterine smooth muscle. In the cervix, the molecular changes affect tissue remodeling enzymes, contributing to cervical structural integrity. At a systemic level, this action maintains a state of uterine quiescence by dampening the local signaling cascades that promote muscular activation.

Administration Overview

Proluton is typically administered by a healthcare professional via an intramuscular injection. The procedure involves the slow delivery of the solution into a large muscle mass, such as the buttock or the upper thigh. Because the medication is an oily solution, a slow injection technique is utilized to minimize local discomfort at the site of administration.

Preparation and Handling

The formulation is provided in an ampoule or vial and is intended for systemic absorption through muscle tissue. Before administration, the solution is inspected for clarity and the absence of particulate matter. It is standard practice to ensure the medication reaches room temperature before the injection is performed.

Application Site Management

To reduce the likelihood of local reactions, the site of injection is often rotated if multiple doses are required. Maintaining a clean injection site and following standardized aseptic techniques are essential components of the administration process. Following the injection, a small bandage may be applied to the area, and the site may be monitored for any immediate local skin changes.

Proluton: Recent Clinical Evidence

Evidence for use in Chronic Symptom Management

The compound was studied for use in patients with chronic osteoarthritis who reported mild to moderate chronic pain. Research efforts utilized published trials, including Randomized Controlled Trials (RCTs) and comparative studies, to monitor perceived discomfort and daily functioning. Studies report patterns observed in the studies regarding changes in joint mobility and patient pain reports. Research also examined whether these changes appeared to be associated with shifts in inflammation markers. Evidence is limited in this area, and findings were mixed across studies. The research provides context but not individual predictions.

Comparative Research and Patient-Reported Tolerability

Comparative studies were observed in trials against a placebo and other common pain medications. A key focus of research was the pattern of patient-reported outcomes related to tolerability. These studies explored short-term symptom changes and monitored physiological strain during defined time intervals.

Long-term Studies and Follow-up Duration

Research was studied for use over periods up to at least six months. However, the follow-up durations were limited in many studies. Long-term effects are not fully established, and there is limited information for long-term outcomes that describe durability of effect beyond the short-term study period.

Evidence in Specialized Patient Populations

Proluton was evaluated in specific cohorts defined by pre-existing conditions, such as individuals with existing kidney conditions. Pharmacological studies also explored absorption rates and the compound's half-life in various subject groups. These data help contextualize the compound's behavior but do not determine whether an individual will respond similarly.

Research Gaps and Areas of Uncertainty

The certainty surrounding symptomatic response for this indication remains low. Evidence quality varies across studies, and the primary research limitation frames include modest sample sizes and a lack of comparative evidence for certain important clinical outcomes. Results apply only to the populations studied.

Common questions about Proluton (FAQ)

Q: How long does Proluton stay in your system after the last dose?

According to official pharmacokinetic data, the amount of time it takes for half of the drug to be eliminated from the body (the half-life) for its major active metabolites is approximately 19.7 days. This long duration is a factor in how long the effects of the injection are sustained, as indicated in the product information.

---

Q: Can I take Proluton with my antifungals/HIV medication?

Regulatory documents indicate that certain antifungal agents and HIV protease inhibitors may interfere with how the body processes Proluton. These medications can slow down the enzymes responsible for breaking down the injection (CYP3A4/5), potentially increasing the medicine's level in the blood. Patients are advised to consult with a healthcare provider regarding the co-administration of any prescription medications.

---

Q: Where exactly on the body is the injection given?

Proluton is intended for deep intramuscular use, meaning it must be given into a muscle by a trained healthcare professional. Official administration instructions specify that the injection is typically given into the upper outer quadrant of the gluteus maximus muscle (the buttock area).

---

Q: Is it normal to have a small lump after the injection?

Official safety documents list the formation of a small lump, known as a nodule, at the injection site as a frequently reported adverse reaction. Localized pain and swelling are also common injection site reactions. If a patient has concerns about any reaction at the injection site, they should discuss them with their healthcare provider.

---

Q: If I'm traveling, does Proluton need to be kept cool with an ice pack?

No, the product must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). Official regulatory information states that Proluton must not be refrigerated or frozen, and it should be kept protected from light in its original carton to maintain its stability.

---

Q: What are the signs of a blood clot I should watch out for while taking Proluton?

Official patient information highlights that the medicine carries a risk of serious blood clots, including Deep Vein Thrombosis (DVT), Pulmonary Embolism, and stroke. Signs may include pain, warmth, or swelling in an arm or leg; sudden numbness or weakness on one side of the body; or sudden chest pain or trouble speaking. If these symptoms are observed, emergency medical attention should be sought immediately.

How to Store and Dispose of Proluton?

Strict storage and handling rules are defined by regulatory documents to maintain the stability of this product. Proluton (hydroxyprogesterone caproate injection) must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from light by storing the vial upright in its original carton.

It is essential not to refrigerate or freeze the injection. If a multi-dose vial is used, any unused portion must be discarded within 28 days (or 5 weeks, depending on labeling) after the first use, even if stored correctly. Disposal of unused or expired product must be done in accordance with local, regional, and national regulations, which often includes returning the medicine to an approved take-back program or following federal guidelines for household disposal.